New Medicine Service (NMS)
The New Medicine Service (NMS) was the fourth Advanced Service to be added to the Community Pharmacy Contractual Framework (CPCF); it commenced on 1st October 2011.
The service provides support for people with long-term conditions newly prescribed a medicine to help improve medicines adherence; it is focused on specific patient groups and conditions.
Visit CPE for more info on the following:
- Introduction and background
- Service specification and other documentation
- Getting ready to provide the service
- Providing the service
- Communicating and working with GP practices
- IT support
- Clarification around sub-contracting of NMS
- Funding and claiming payment
- Frequently Asked Questions
- Resources
- Statistics and evaluation
- Provide feedback on national pharmacy services
The conditions eligible for the service are:
- acute coronary syndromes
- asthma
- atrial fibrillation
- chronic obstructive pulmonary disease (COPD)
- coronary heart disease
- depression (only those ≥18 years of age)
- diabetes (Type 2)
- epilepsy
- glaucoma
- gout
- heart failure
- hypercholesterolaemia
- hypertension
- long term risks of venous thromboembolism/embolism
- osteoporosis
- Parkinson’s disease
- stroke/transient ischemic attack
- urinary incontinence/retention
NHS England has updated the NMS Eligible Drug List with changes taking effect from Wednesday 29 October 2025.
View the drugs list via NHSBSA
Updated CPPE NMS resources:
The Centre for Pharmacy Postgraduate Education (CPPE) has updated their New Medicine Service (NMS) resources following the recent expansion to the service. Both CPPE’s NMS e-learning and NMS webpage have now been updated to include a section on depression following its addition as a therapeutic area.
🔗View the updated CPPE NMS e-learning
🔗View the updated CPPE NMS webpage
